Review articleergotamine (cas 113-15-5) and nicergoline – Facts and myths

Add time:08/21/2019    Source:sciencedirect.com

Ergotamine, being a representative of naturally occurring ergoline alkaloids, derived from d-lysergic acid, and nicergoline, a d-lumilysergic acid derivative belonging to semi-synthetic ergot-derived alkaloids, display diversified affinity for adrenergic, serotoninergic, and dopamine receptors. Although introduction of triptans marginalized use of ergotamine, nicergoline is used in cerebral metabolic-vascular disorders, and dementia. Additionally, nicergoline exhibits a safety profile comparable to that of placebo, and none of the reviewed studies reported any incidence of fibrosis or ergotism with nicergoline treatment.In line with the recent data, activation of 5-HT2B receptor by ergot derivatives i.e. ergotamine, methysergide, pergolide, and carbegoline is involved in pathogenesis of drug-induced valvulopathy. In contrary structurally related drugs – lisuride and terguride do not increase the risk of valvular heart disease. It seems, that more detailed mechanistic studies on nicergoline and ergotamine might be beneficial for determining structural requirements related to activation of G-protein as well as alternative signal transduction pathways e.g. β-arrestins or different kinases, and responsible for drug liabilities.

We also recommend Trading Suppliers and Manufacturers of ergotamine (cas 113-15-5). Pls Click Website Link as below: cas 113-15-5 suppliers

Prev:Research PaperHaematological effects of 2-Phenoxyethanol (cas 112-99-6) and etomidate in carp (Cyprinus carpio L.)
Next:Neuropharmacology and analgesiaRole of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine (cas 113-15-5) and valerenic acid in the rat formalin test)